Trials / Unknown
UnknownNCT02822547
Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults
Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults.
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 253 (estimated)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
Patients will receive Peginterferon alfa-2a according to the standard medical practice but the observation period is 12 weeks
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peginterferon alfa-2a | Patients will receive Peginterferon alfa-2a according to the standard medical practice |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2016-09-01
- Completion
- 2016-12-01
- First posted
- 2016-07-04
- Last updated
- 2016-07-04
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02822547. Inclusion in this directory is not an endorsement.